Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3)

Cell Death and Disease

Volumn 1, Issue 1, 2010, Pages

  Sassone, J ^a   Colciago, C ^a   Marchi, P ^b   Ascardi, C ^a,c   Alberti, L ^d   Di Pardo, A ^b   Zippel, R ^a   Sipione, S ^b   Silani, V ^a   Ciammola, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

BNip3; Huntingtons disease; mitochondria

Indexed keywords

BCL 2 ADENOVIRUS E1B 19 KDA INTERACTING PROTYEIN; DIMER; HUNTINGTIN; MONOMER; PLASMID DNA; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BNIP3 PROTEIN, HUMAN; BNIP3 PROTEIN, MOUSE; HD PROTEIN, HUMAN; HUNTINGTON PROTEIN, MOUSE; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; NERVE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL CULTURE; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MITOCHONDRION; MOUSE; MUTANT; MYOBLAST; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANIMAL; CELL LINE; DISEASE MODEL; GENETICS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MUSCLE CELL; MUTATION;

ADENOVIRIDAE; MUS;

ANIMALS; CELL LINE; DIMERIZATION; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MICE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MUSCLE CELLS; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS;

EID: 79951482092     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2009.6     Document Type: Article

References (40)

1. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntingtons disease caudate nucleus. Ann Neurol 1996; 39: 385-389. (Pubitemid 26100764)
2. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH. Biochemical abnormalities and excitotoxicity in Huntingtons disease brain. Ann Neurol 1999; 45: 25-32. (Pubitemid 29036428)
3. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M et al. HD CAG repeat implicates a dominant property of Huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005; 14: 2871-2880. (Pubitemid 41418792)
4. Saft C, Zange J, Andrich J, Müller K, Lindenberg K, Landwehrmeyer B et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntingtons disease. Mov Disord 2005; 20: 674-679.
5. Squitieri F, Cannella M, Sgarbi G, Maglione V, Falleni A, Lenzi P et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev 2006; 127: 217-220. (Pubitemid 43165622)
6. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler Jr JF et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 1999; 5: 1194-1198. (Pubitemid 29474426)
7. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ et al. Early mitochondrial calcium defects in Huntingtons disease are a direct effect of polyglutamines. Nat Neurosci 2002; 5: 731-736. (Pubitemid 34827590)
8. Ciammola A, Sassone J, Alberti L, Meola G, Mancinelli E, Russo MA et al. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntingtons disease subjects. Cell Death Differ 2006; 13: 2068-2078. (Pubitemid 44742690)
9. Almeida S, Sarmento-Ribeiro AB, Januário C, Rego AC, Oliveira CR. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntingtons disease patients. Biochem Biophys Res Commun 2008; 374: 599-603.
10. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated Huntingtin. Mol Biol Cell 2006; 17: 1652-1663. (Pubitemid 44011583)
11. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntingtons disease. Neuron 2005; 47: 29-41. (Pubitemid 40922848)
12. Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntingtons disease. Arch Biochem Biophys 2003; 410: 1-6. (Pubitemid 36268790)
13. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000; 7: 1182-1191. (Pubitemid 32042225)
14. Frazier DP, Wilson A, Graham RM, Thompson JW, Bishopric NH, Webster KA. Acidosis regulates the stability, hydrophobicity, and activity of the BH3-only protein Bnip3. Antioxid Redox Signal 2006; 8: 1625-1634. (Pubitemid 44726337)
15. Lee H, Paik SG. Regulation of BNIP3 in normal and cancer cells. Mol Cells 2006; 21: 1-6.
16. Burton TR, Henson ES, Baijal P, Eisenstat DD, Gibson SB. The pro-cell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: implications for glioblastoma multiforme tumor cell survival under hypoxia. Int J Cancer 2006; 118: 1660-1669. (Pubitemid 43376429)
17. Webster KA, Graham RM, Bishopric NH. BNip3 and signal-specific programmed death in the heart. J Mol Cell Cardiol 2005; 38: 35-45. (Pubitemid 40038650)
18. Graham RM, Thompson JW, Wei J, Bishopric NH, Webster KA. Regulation of Bnip3 death pathways by calcium, phosphorylation, and hypoxia-reoxygenation. Antioxid Redox Signal 2007; 9: 1309-1315. (Pubitemid 47255010)
19. Vande Velde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 2000; 20: 5454-5468. (Pubitemid 30482883)
20. Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, Reed JC et al. BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 2000; 275: 1439-1448. (Pubitemid 30051204)
21. Kim JY, Cho JJ, Ha J, Park JH. The carboxy terminal C-tail of BNip3 is crucial in induction of mitochondrial permeability transition in isolated mitochondria. Arch Biochem Biophys 2002; 398: 147-152. (Pubitemid 34848580)
22. Hamacher-Brady A, Brady NR, Logue SE, Sayen MR, Jinno M, Kirshenbaum LA et al. Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy. Cell Death Differ 2007; 14: 146-157. (Pubitemid 44911902)
23. Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci USA 2002; 99: 12825-12830.
24. Regula KM, Ens K, Kirshenbaum LA. Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res 2002; 91: 226-231. (Pubitemid 34875677)
25. Bocharov EV, Pustovalova YE, Pavlov KV, Volynsk PE, Goncharuk MV, Ermolyuk YS et al. Unique dimeric structure of BNip3 transmembrane domain suggests membrane permeabilization as a cell death trigger. J Biol Chem 2007; 282: 16256-16266. (Pubitemid 47100372)
26. Chen G, Ray R, Dubik D, Shi L, Cizeau J, Bleackley RC et al. The E1B 19K/Bcl-2-binding protein Nip3 is a dimeric mitochondrial protein that activates apoptosis. J Exp Med 1997; 186: 1975-1983. (Pubitemid 28013681)
27. Mellor HR, Harris AL. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev 2007; 26: 553-566. (Pubitemid 350115110)
28. Tracy K, Macleod KF. Regulation of mitochondrial integrity, autophagy and cell survival by BNIP3. Autophagy 2007; 3: 616-619. (Pubitemid 350060062)
29. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K et al. Regulated targeting of BAX to mitochondria. J Cell Biol 1998; 143: 207-215. (Pubitemid 28480529)
30. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506. (Pubitemid 26374323)
31. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R et al. A YAC mouse model for Huntingtons disease with full-length mutant Huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999; 23: 181-192. (Pubitemid 29262475)
32. Gao S, Fu W, Dürrenberger M, De Geyter C, Zhang H. Membrane translocation and oligomerization of hBok are triggered in response to apoptotic stimuli and Bnip3. Cell Mol Life Sci 2005; 62: 1015-1024. (Pubitemid 40655617)
33. Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003; 22: 4734-4744. (Pubitemid 36976448)
34. Browne SE. Mitochondria and Huntingtons disease pathogenesis: insight from genetic and chemical models. Ann NY Acad Sci 2008; 1147: 358-382.
35. Bossy-Wetzel E, Petrilli A, Knott AB. Mutant Huntingtin and mitochondrial dysfunction. Trends Neurosci 2008; 31: 609-616.
36. Arenas J, Campos Y, Ribacoba R, Martín MA, Rubio JC, Ablanedo P et al. Complex I defect in muscle from patients with Huntingtons disease. Ann Neurol 1998; 43: 397-400.
37. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ et al. Abnormal in vivo skeletal muscle energy metabolism in Huntingtons disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72-76. (Pubitemid 30432433)
38. Kubli DA, Ycaza JE, Gustafsson AB. Bnip3 mediates mitochondrial dysfunction and cell death through Bax and Bak. Biochem J 2007; 405: 407-415. (Pubitemid 47172037)
39. Diwan A, Krenz M, Syed FM,Wansapura J, Ren X, Koesters AG et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest 2007; 117: 2825-2833. (Pubitemid 47529613)
40. Graham RM, Frazier DP, Thompson JW, Haliko S, Li H, Wasserlauf BJ et al. A unique pathway of cardiac myocyte death caused by hypoxia-acidosis. J Exp Biol 2004; 207: 3189-3200. (Pubitemid 39275293)